肠道菌群视角下非酒精性脂肪性肝病的治疗策略

doi:10.12114/j.issn.1007-9572.2022.0651

中国全科医学 ›› 2023, Vol. 26 ›› Issue (06): 742-748.DOI: 10.12114/j.issn.1007-9572.2022.0651

肠道菌群视角下非酒精性脂肪性肝病的治疗策略

傅伟强¹, 周剑波¹, 吴雄健², 黄才斌²^,^*()

1．341000　江西省赣州市，赣南医学院第一临床医学院
2．341000　江西省赣州市，赣南医学院第一附属医院消化内科

收稿日期:2022-07-15 修回日期:2022-09-10 出版日期:2023-02-20 发布日期:2022-10-27
通讯作者: 黄才斌
傅伟强，周剑波，吴雄健，等.肠道菌群视角下非酒精性脂肪性肝病的治疗策略[J].中国全科医学，2023，26（6）：742-748. [www.chinagp.net]
作者贡献：傅伟强负责文章的构思和设计、文献整理、撰写论文；周剑波负责文献收集；吴雄健负责论文修订；黄才斌负责文章的质量控制及审校，对文章整体负责、监督管理。
基金资助:
江西省自然科学基金资助项目（20202BAB206009）——LncRNA NEAT1诱导线粒体功能紊乱/氧化应激诱发肝纤维化的机制研究

Treatment Strategy of Nonalcoholic Fatty Liver Disease Targeting the Intestinal Microbiota

FU Weiqiang¹, ZHOU Jianbo¹, WU Xiongjian², HUANG Caibin²^,^*()

1. The First Clinical Medical College of Gannan Medical University, Ganzhou 341000, China
2. Department of Gastroenterology, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China

Received:2022-07-15 Revised:2022-09-10 Published:2023-02-20 Online:2022-10-27
Contact: HUANG Caibin
About author:
FU W Q, ZHOU J B, WU X J, et al. Treatment strategy of nonalcoholic fatty liver disease targeting the intestinal microbiota[J]. Chinese General Practice, 2023, 26 (6) : 742-748.

分享到

摘要/Abstract

摘要： 非酒精性脂肪性肝病（NAFLD）是最常见的慢性肝脏疾病，其疾病谱主要包括非酒精性肝脂肪变、非酒精性脂肪性肝炎（NASH）、肝硬化及肝细胞癌（HCC）。近年研究揭示肠-肝轴与NAFLD发生、发展相关，运动、饮食、微生态制剂、抗生素、粪菌移植、噬菌体等干预措施均可以通过改变肠道菌群缓解NAFLD。本文综述了肠道菌群与NAFLD的关系和作用机制及以调整肠道菌群为NAFLD治疗靶点的研究进展，发现肠道菌群与NAFLD密切相关，调控肠道菌群可作为NAFLD治疗的新靶点，将为临床医师治疗NAFLD提供新的思路和参考。

关键词: 非酒精性脂肪性肝病, 胃肠道微生物组, 肠道菌群, 治疗, 代谢综合征, 微生态制剂, 粪菌移植

Abstract:

Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease, represents a spectrum of nonalcoholic hepatic steatosis, nonalcoholic steatohepatitis, liver cirrhosis and hepatocellular carcinoma. Recent studies have revealed that the gut-liver axis is associated with the development of NAFLD. Intervention measures such as exercise, diet, microecological preparations, antibiotics, fecal microbiota transplantation and bacteriophage can alleviate NAFLD by improving intestinal microbiota. We reviewed recent advances in the relationship and mechanism between intestinal microbiota and NAFLD as well as treatment of NAFLD targeting the intestinal microbiota, and summarized that intestinal microbiota is closely related to NAFLD, and the regulation of intestinal microbiota can be used as a new target for NAFLD treatment, which will provide new ideas and references for clinicians in the diagnosis and treatment of NAFLD.

Key words: Non-alcoholic fatty liver disease, Gastrointestinal microbiome, Intestinal flora, Therapy, Metabolic syndrome, Microecological preparation, Fecal microbiota transplantation

傅伟强,周剑波,吴雄健,等. 肠道菌群视角下非酒精性脂肪性肝病的治疗策略[J]. 中国全科医学, 2023, 26(06): 742-748. DOI: 10.12114/j.issn.1007-9572.2022.0651.
FU Weiqiang,ZHOU Jianbo,WU Xiongjian, et al. Treatment Strategy of Nonalcoholic Fatty Liver Disease Targeting the Intestinal Microbiota[J]. Chinese General Practice, 2023, 26(06): 742-748. DOI: 10.12114/j.issn.1007-9572.2022.0651.

图/表 1

参考文献 66

[1]	POWELL E E, WONG V W S, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet，2021，397(10290):2212-2224. DOI：10.1016/S0140-6736(20)32511-3.
[2]	CARIOU B, BYRNE C D, LOOMBA R，et al. Nonalcoholic fatty liver disease as a metabolic disease in humans：a literature review[J]. Diabetes Obes Metab，2021，23(5):1069-1083. DOI：10.1111/dom.14322.
[3]	MÉNDEZ-SÁNCHEZ N, DÍAZ-OROZCO L E. Editorial：international consensus recommendations to replace the terminology of non-alcoholic fatty liver disease （NAFLD） with metabolic-associated fatty liver disease （MAFLD）[J]. Med Sci Monit，2021，27:e933860. DOI：10.12659/MSM.933860.
[4]	GE X J, ZHENG L M, WANG M，et al. Prevalence trends in non-alcoholic fatty liver disease at the global，regional and national levels，1990-2017：a population-based observational study[J]. BMJ Open，2020，10(8):e036663. DOI：10.1136/bmjopen-2019-036663.
[5]	AHMAD M I, KHAN M U, KODALI S，et al. Hepatocellular carcinoma due to nonalcoholic fatty liver disease：current concepts and future challenges[J]. J Hepatocell Carcinoma，2022，9:477-496. DOI：10.2147/JHC.S344559.
[6]	NOUREDDIN M, SANYAL A J. Pathogenesis of NASH：the impact of multiple pathways[J]. Curr Hepatol Rep，2018，17(4):350-360. DOI：10.1007/s11901-018-0425-7.
[7]	KIM W, KIM B G, LEE J S，et al. Randomised clinical trial：the efficacy and safety of oltipraz，a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther，2017，45(8):1073-1083. DOI：10.1111/apt.13981.
[8]	HOOZEMANS J, DE BRAUW M, NIEUWDORP M，et al. Gut microbiome and metabolites in patients with NAFLD and after bariatric surgery：a comprehensive review[J]. Metabolites，2021，11(6):353. DOI：10.3390/metabo11060353.
[9]	VALLIANOU N, STRATIGOU T, CHRISTODOULATOS G S，et al. Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders：current evidence and perspectives[J]. Curr Obes Rep，2019，8(3):317-332. DOI：10.1007/s13679-019-00352-2.
[10]	NOGACKA A M, GÓMEZ-MARTÍN M, SUÁREZ A，et al. Xenobiotics formed during food processing：their relation with the intestinal microbiota and colorectal cancer[J]. Int J Mol Sci，2019，20(8):E2051. DOI：10.3390/ijms20082051.
[11]	WAN M L Y, LING K H, EL-NEZAMI H，et al. Influence of functional food components on gut health[J]. Crit Rev Food Sci Nutr，2019，59(12):1927-1936. DOI：10.1080/10408398.2018.1433629.
[12]	OLIPHANT K, ALLEN-VERCOE E. Macronutrient metabolism by the human gut microbiome：major fermentation by-products and their impact on host health[J]. Microbiome，2019，7(1):91. DOI：10.1186/s40168-019-0704-8.
[13]	YAN X F, JIN J J, SU X H，et al. Intestinal flora modulates blood pressure by regulating the synthesis of intestinal-derived corticosterone in high salt-induced hypertension[J]. Circ Res，2020，126(7):839-853. DOI：10.1161/CIRCRESAHA.119.316394.
[14]	ZHAO Y Z, ZHOU J L, LIU J Q，et al. Metagenome of gut microbiota of children with nonalcoholic fatty liver disease[J]. Front Pediatr，2019，7:518. DOI：10.3389/fped.2019.00518.
[15]	HOYLES L, FERNÁNDEZ-REAL J M, FEDERICI M，et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women[J]. Nat Med，2018，24(7):1070-1080. DOI：10.1038/s41591-018-0061-3.
[16]	YUAN J, CHEN C, CUI J H，et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae[J]. Cell Metab，2019，30(6):1172. DOI：10.1016/j.cmet.2019.11.006.
[17]	SHARPTON S R, AJMERA V, LOOMBA R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease：from composition to function[J]. Clin Gastroenterol Hepatol，2019，17(2):296-306. DOI：10.1016/j.cgh.2018.08.065.
[18]	DE MUNCK T J I, XU P, VERWIJS H J A，et al. Intestinal permeability in human nonalcoholic fatty liver disease：a systematic review and meta-analysis[J]. Liver Int，2020，40(12):2906-2916. DOI：10.1111/liv.14696
[19]	CHEN J, ZHENG M H, LIU J，et al. Ratio of conjugated chenodeoxycholic to muricholic acids is associated with severity of nonalcoholic steatohepatitis[J]. Obesity （Silver Spring），2019，27(12):2055-2066. DOI：10.1002/oby.22627.
[20]	JI Y, YIN Y, SUN L J，et al. The molecular and mechanistic insights based on gut-liver axis：nutritional target for non-alcoholic fatty liver disease （NAFLD） improvement[J]. Int J Mol Sci，2020，21(9):E3066. DOI：10.3390/ijms21093066.
[21]	ZHAO S, JANG C, LIU J，et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate[J]. Nature，2020，579(7800):586-591. DOI：10.1038/s41586-020-2101-7.
[22]	VIVEIROS K. The role of life style modifications in comprehensive non-alcoholic fatty liver disease treatment[J]. Clin Liver Dis （Hoboken），2021，17(1):11-14. DOI：10.1002/cld.1007.
[23]	BARTON W, PENNEY N C, CRONIN O，et al. The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level[J]. Gut，2018，67(4):625-633. DOI：10.1136/gutjnl-2016-313627.
[24]	VALLIANOU N, DALAMAGA M, STRATIGOU T，et al. Do antibiotics cause obesity through long-term alterations in the gut microbiome? A review of current evidence[J]. Curr Obes Rep，2021，10(3):244-262. DOI：10.1007/s13679-021-00438-w.
[25]	CARBAJO-PESCADOR S, PORRAS D, GARCÍA-MEDIAVILLA M V，et al. Beneficial effects of exercise on gut microbiota functionality and barrier integrity，and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease[J]. Dis Model Mech，2019，12(5):dmm039206. DOI：10.1242/dmm.039206.
[26]	CHENG R T, WANG L, LE S L，et al. A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease[J]. Nat Commun，2022，13(1):2555. DOI：10.1038/s41467-022-29968-0.
[27]	VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLA-BERTOT L，et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology，2015，149(2):367-378.e5;quize14-15. DOI：10.1053/j.gastro.2015.04.005.
[28]	SAVARD C, TARTAGLIONE E V, KUVER R，et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis[J]. Hepatology，2013，57(1):81-92. DOI：10.1002/hep.25789.
[29]	CHALASANI N, YOUNOSSI Z, LAVINE J E，et al. The diagnosis and management of nonalcoholic fatty liver disease：practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology，2018，67(1):328-357. DOI：10.1002/hep.29367.
[30]	ALLER R, BURGUEÑO GOMEZ B, SIGÜENZA R，et al. Comparative study of overweight and obese patients with nonalcoholic fatty liver disease[J]. Rev Esp Enferm Dig，2019，111(4):256-263. DOI：10.17235/reed.2019.5926/2018.
[31]	CALABRESE F M, DISCIGLIO V, FRANCO I，et al. A low glycemic index Mediterranean diet combined with aerobic physical activity rearranges the gut microbiota signature in NAFLD patients[J]. Nutrients，2022，14(9):1773. DOI：10.3390/nu14091773.
[32]	HILL C, GUARNER F, REID G，et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nat Rev Gastroenterol Hepatol，2014，11(8):506-514. DOI：10.1038/nrgastro.2014.66.
[33]	MOHAMAD NOR M H, AYOB N, MOKHTAR N M，et al. The effect of probiotics （MCP® BCMC® strains） on hepatic steatosis，small intestinal mucosal immune function，and intestinal barrier in patients with non-alcoholic fatty liver disease[J]. Nutrients，2021，13(9):3192. DOI：10.3390/nu13093192.
[34]	LUO M M, YAN J B, WU L Y，et al. Probiotics alleviated nonalcoholic fatty liver disease in high-fat diet-fed rats via gut microbiota/FXR/FGF15 signaling pathway[J]. J Immunol Res，2021，2021:2264737. DOI：10.1155/2021/2264737.
[35]	PARK E J, LEE Y S, KIM S M，et al. Beneficial effects of Lactobacillus plantarum strains on non-alcoholic fatty liver disease in high fat/high fructose diet-fed rats[J]. Nutrients，2020，12(2):E542. DOI：10.3390/nu12020542.
[36]	AHN S B, JUN D W, KANG B K，et al. Randomized，double-blind，placebo-controlled study of a multi species probiotic mixture in nonalcoholic fatty liver disease[J]. Sci Rep，2019，9(1):5688. DOI：10.1038/s41598-019-42059-3.
[37]	DUSEJA A, ACHARYA S K, MEHTA M，et al. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease （NAFLD）：a randomised，double-blind，proof of concept study[J]. BMJ Open Gastroenterol，2019，6(1):e000315. DOI：10.1136/bmjgast-2019-000315.
[38]	LAVEKAR A S, V RAJE D, MANOHAR T，et al. Role of probiotics in the treatment of nonalcoholic fatty liver disease：a meta-analysis[J]. Euroasian J Hepatogastroenterol，2017，7(2):130-137. DOI：10.5005/jp-journals-10018-1233.
[39]	HOLSCHER H D. Dietary fiber and prebiotics and the gastrointestinal microbiota[J]. Gut Microbes，2017，8(2):172-184. DOI：10.1080/19490976.2017.1290756.
[40]	PLOVIER H, EVERARD A, DRUART C，et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice[J]. Nat Med，2017，23(1):107-113. DOI：10.1038/nm.4236.
[41]	SINGH D P, KHARE P, ZHU J，et al. A novel cobiotic-based preventive approach against high-fat diet-induced adiposity，nonalcoholic fatty liver and gut derangement in mice[J]. Int J Obes （Lond），2016，40(3):487-496. DOI：10.1038/ijo.2015.197.
[42]	BOMHOF M R, PARNELL J A, RAMAY H R，et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic：a pilot clinical trial[J]. Eur J Nutr，2019，58(4):1735-1745. DOI：10.1007/s00394-018-1721-2.
[43]	CHONG P L, LAIGHT D, ASPINALL R J，et al. A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease[J]. BMC Gastroenterol，2021，21(1):144. DOI：10.1186/s12876-021-01660-5.
[44]	KOBYLIAK N, ABENAVOLI L, MYKHALCHYSHYN G，et al. A multi-strain probiotic reduces the fatty liver index，cytokines and aminotransferase levels in NAFLD patients：evidence from a randomized clinical trial[J]. J Gastrointestin Liver Dis，2018，27(1):41-49. DOI：10.15403/jgld.2014.1121.271.kby.
[45]	MOFIDI F, POUSTCHI H, YARI Z，et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease：a pilot，randomised，double-blind，placebo-controlled，clinical trial[J]. Br J Nutr，2017，117(5):662-668. DOI：10.1017/S0007114517000204.
[46]	SCORLETTI E, AFOLABI P R, MILES E A，et al. Synbiotics alter fecal microbiomes，but not liver fat or fibrosis，in a randomized trial of patients with nonalcoholic fatty liver disease[J]. Gastroenterology，2020，158(6):1597-1610.e7. DOI：10.1053/j.gastro.2020.01.031.
[47]	FEROLLA S M, COUTO C A, COSTA-SILVA L，et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters，but not on gut permeability in a population with nonalcoholic steatohepatitis[J]. Nutrients，2016，8(7):397. DOI：10.3390/nu8070397.
[48]	VALLIANOU N, STRATIGOU T, CHRISTODOULATOS G S，et al. Probiotics，prebiotics，synbiotics，postbiotics，and obesity：current evidence，controversies，and perspectives[J]. Curr Obes Rep，2020，9(3):179-192. DOI：10.1007/s13679-020-00379-w.
[49]	VALLEJO-CORDOBA B, CASTRO-LÓPEZ C, GARCÍA H S，et al. Postbiotics and paraprobiotics：a review of current evidence and emerging trends[J]. Adv Food Nutr Res，2020，94:1-34. DOI：10.1016/bs.afnr.2020.06.001.
[50]	PELUZIO M D C G, MARTINEZ J A, MILAGRO F I. Postbiotics：metabolites and mechanisms involved in microbiota-host interactions[J]. Trends Food Sci Technol，2021，108:11-26. DOI：10.1016/j.tifs.2020.12.004.
[51]	WANG S H, AHMADI S, NAGPAL R，et al. Lipoteichoic acid from the cell wall of a heat killed Lactobacillus paracasei D3-5 ameliorates aging-related leaky gut，inflammation and improves physical and cognitive functions：from C. elegans to mice[J]. Geroscience，2020，42(1):333-352. DOI：10.1007/s11357-019-00137-4.
[52]	MA L Y, NI Y H, WANG Z，et al. Spermidine improves gut barrier integrity and gut microbiota function in diet-induced obese mice[J]. Gut Microbes，2020，12(1):1-19. DOI：10.1080/19490976.2020.1832857.
[53]	中华医学会肠外肠内营养学分会，中国国际医疗保健促进交流会加速康复外科分会，中国微生态治疗创新联盟，等. 菌群移植标准化方法学的建立与临床应用中国专家共识[J]. 中华胃肠外科杂志，2020，23(S1):5-13. DOI：10.3760/cma.j.cn.441530-20200420-00231.
[54]	ZHOU D, PAN Q, SHEN F，et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep，2017，7(1):1529. DOI：10.1038/s41598-017-01751-y.
[55]	VRIEZE A, VAN NOOD E, HOLLEMAN F，et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J]. Gastroenterology，2012，143(4):913-916.e7. DOI：10.1053/j.gastro.2012.06.031.
[56]	WITJES J J, SMITS L P, PEKMEZ C T，et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis[J]. Hepatol Commun，2020，4(11):1578-1590. DOI：10.1002/hep4.1601.
[57]	CRAVEN L, RAHMAN A, NAIR PARVATHY S，et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability：a randomized control trial[J]. Am J Gastroenterol，2020，115(7):1055-1065. DOI：10.14309/ajg.0000000000000661.
[58]	KAJI K, TAKAYA H, SAIKAWA S，et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity[J]. World J Gastroenterol，2017，23(47):8355-8366. DOI：10.3748/wjg.v23.i47.8355.
[59]	JIAN J, NIE M T, XIANG B Y，et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids[J]. Front Pharmacol，2022，13:841132. DOI：10.3389/fphar.2022.841132.
[60]	FUJINAGA Y, KAWARATANI H, KAYA D，et al. Effective combination therapy of angiotensin-Ⅱ receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis[J]. Int J Mol Sci，2020，21(15):E5589. DOI：10.3390/ijms21155589.
[61]	GANGARAPU V, INCE A T, BAYSAL B，et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol，2015，27(7):840-845. DOI：10.1097/MEG.0000000000000348.
[62]	COBBOLD J F L, ATKINSON S, MARCHESI J R，et al. Rifaximin in non-alcoholic steatohepatitis：an open-label pilot study[J]. Hepatol Res，2018，48(1):69-77. DOI：10.1111/hepr.12904.
[63]	SUN D L, ZUO C, HUANG W，et al. Triclosan targeting of gut microbiome ameliorates hepatic steatosis in high fat diet-fed mice[J]. J Antibiot （Tokyo），2022，75(6):341-353. DOI：10.1038/s41429-022-00522-w.
[64]	MAHANA D, TRENT C M, KURTZ Z D，et al. Antibiotic perturbation of the murine gut microbiome enhances the adiposity，insulin resistance，and liver disease associated with high-fat diet[J]. Genome Med，2016，8(1):48. DOI：10.1186/s13073-016-0297-9.
[65]	GÓRSKI A, BOLLYKY P L, PRZYBYLSKI M，et al. Perspectives of phage therapy in non-bacterial infections[J]. Front Microbiol，2018，9:3306. DOI：10.3389/fmicb.2018.03306.
[66]	DUAN Y, LLORENTE C, LANG S，et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease[J]. Nature，2019，575(7783):505-511. DOI：10.1038/s41586-019-1742-x.

肠道菌群视角下非酒精性脂肪性肝病的治疗策略

Treatment Strategy of Nonalcoholic Fatty Liver Disease Targeting the Intestinal Microbiota

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 66

相关文章 15

编辑推荐

Metrics

留言

[1]	张迪, 李鸿鹏, 马江, 聂谦, 孙剑峰, 吴志鹏, 张宏才, 赵珏. 眼针带针运动对经皮冠状动脉介入术治疗患者术后心率变异性及预后的影响研究[J]. 中国全科医学, 2023, 26(36): 4535-4544.
[2]	刘炳蔚, 王静, 乔雪, 牟思霖, 时光喜, 李静蔚. 雌激素受体阳性乳腺癌患者内分泌治疗期高脂血症的临床特征及中药用药分析：基于真实世界研究[J]. 中国全科医学, 2023, 26(36): 4558-4564.
[3]	中华医学会心身医学分会进食障碍协作学组, 中华医学会精神医学分会进食障碍研究协作组, 陈妍, 陈涵, 刘兰英, 孔庆梅, 乔慧芬, 张岚, 李雪霓, 匡桂芳, 张大荣, 栗克清, 王振, 陈珏. 中国神经性贪食诊疗专家共识[J]. 中国全科医学, 2023, 26(36): 4487-4497.
[4]	慢性阻塞性肺疾病中西医结合管理专家共识写作组. 慢性阻塞性肺疾病中西医结合管理专家共识（2023版）[J]. 中国全科医学, 2023, 26(35): 4359-4371.
[5]	柳浦青, 陈静文, 寿张轩. 基于Beers标准评价住院老年非瓣膜性心房颤动患者直接口服抗凝药物的潜在不适当用药研究[J]. 中国全科医学, 2023, 26(35): 4388-4393.
[6]	李殿江, 潘恩春, 孙中明, 文进博, 王苗苗, 武鸣, 沈冲. 社区2型糖尿病患者临床惰性现状及其影响因素分析[J]. 中国全科医学, 2023, 26(34): 4296-4301.
[7]	林恺, 姚弥, 陈章, 纪欣鑫, 林润琪, 陈永松, Sim MOIRA. 2型糖尿病治疗负担的概念框架及应对方式：基于视频记录分析[J]. 中国全科医学, 2023, 26(34): 4302-4307.
[8]	姚裕忠, 马晓骏, 宋懽, 钟瑜. 基于"全专精准管理"的糖尿病"1358模式"对社区糖尿病患者的管理效果研究[J]. 中国全科医学, 2023, 26(34): 4308-4314.
[9]	周俞余, 高川, 崔埔安, 王亚平, 何仲. 更年期综合征患者绝经激素治疗中医患共同决策质量的影响因素研究[J]. 中国全科医学, 2023, 26(33): 4181-4186.
[10]	王丽娜, 高鹏飞, 曹帆, 葛莹, 颜维, 何岱昆. 不同性别人群非酒精性脂肪性肝病患病现况及影响因素分析[J]. 中国全科医学, 2023, 26(33): 4143-4151.
[11]	路广琦, 庄明辉, 朱立国, 高景华, 魏戌, 李路广, 于杰. 腰椎管狭窄症的微创治疗实践指南：2022年美国疼痛与神经科学学会指南解读[J]. 中国全科医学, 2023, 26(32): 3995-4000.
[12]	李茜, 张云淑, 严保平, 王健, 马燕娟, 王媛, 秦英杰, 那龙, 任智勇, 孙俊伟, 邓怀丽, 马宏筠, 曲雪慧, 周楠, 司天梅. 注射用利培酮微球（Ⅱ）治疗急性期精神分裂症患者的疗效及安全性研究[J]. 中国全科医学, 2023, 26(32): 4007-4012.
[13]	朱琳, 郭闫葵, 高琛, 陈学志, 王法帅. 单纯西药、中成药及其联合治疗卒中后失眠疗效的网状Meta分析[J]. 中国全科医学, 2023, 26(30): 3823-3832.
[14]	张振东, 蔡斌, 王宏伟, 乔增勇. 肠道菌群及其代谢产物苯乙酰谷氨酰胺在慢性心力衰竭患者中的变化研究[J]. 中国全科医学, 2023, 26(29): 3665-3673.
[15]	韦雨柔, 田佳庆, 肖方骏, 何宪顺, 詹芝玮, 魏腾飞, 林天烨, 何敏聪, 魏秋实. 活血通络胶囊对激素性股骨头坏死大鼠肠道菌群影响的研究[J]. 中国全科医学, 2023, 26(29): 3674-3682.